Guidelines of the German Society of Metabolic and Digestive Diseases for the therapy of dyspesia;Leitlinien der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten zur behandlung der dyspepsie

Zeitschrift fur Gastroenterologie

Volumn 39, Issue 11, 2001, Pages 937-956

  Malfertheiner, P ^a   Holtmann, G ^a   Peitz, U ^a   Birkner, B ^a   Arnold, R ^a   Hotz, J ^a   Leodolter, A ^a   Mossner J ^a   Robra, B P ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTACID AGENT; ANTIDEPRESSANT AGENT; CISAPRIDE; DIMETICONE; DOPAMINE RECEPTOR BLOCKING AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

AUTONOMIC NEUROPATHY; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; REVIEW; STRESS;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; DYSPEPSIA; EVIDENCE-BASED MEDICINE; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED;

EID: 0035190351     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18536     Document Type: Review

References (121)

1. Evaluation of dyspepsia
2. Management of uninvestigated and functional dyspepsia: A working party report for the world congresses of gastroenterology
3. Identification of sub-groups of functional gastrointestinal disorders
4. Practice guidelines, a new reality in Medicine
5. Marve-tarmsymptomer blandt 40-arige i Glostrup: En epidemiologisk undersogelse
6. Peptic ulcer and non-ulcer dyspepsia - A disease and a disorder
7. Nonulcer dyspepsia in a Dutch working population and Helicobacter pylori: Ulcer history as an explanation of an apparent association
8. Prevalence of symptoms of dyspepsia in the community
9. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders
10. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time
11. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia
12. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: A decision analysis
13. RUDER - A prospective, two year multicenter study of risk factors for duodenal ulcer relapse during maintenance therapy with ranitidine
14. Environmental factors and chronic unexplained dyspepsia. Association with acetaminophen but not other analgesics, alcohol, coffee, tea, or smoking
15. Comparison of coffee intake and coffee-induced symptoms in patients with duodenal ulcers, non-ulcer dyspepsia and normal controls
16. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy
17. Evaluation of a questionnaire for the diagnosis of symptomatic gastroesophageal reflux disease (GERD)
18. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia
19. Functional gastroduodenal disorders
20. Childhood functional gastrointestinal disorders
21. Symptoms in gastro-oesophageal reflux disease
22. Importance of reflux symptoms in functional dyspepsia
23. Functional dyspepsia: A classification with guidelines for diagnosis and management
24. Konsensusbericht: Reizdarmsyndrom- Definition, diagnosesicherung, pathophysiologie und therapiemöglichkeiten. Konsensus der Deutschen Gesellschaft und Verdauungs- und Stoffwechselkrankheiten
25. Functional dyspepsia and irritable bowel syndrome: Is there a common pathophysiological basis?
26. Gastrointestinal symptoms cluster into distinct upper and lower groupings consistent with the Rome classification: A three country population-based study
27. Dyspepsia and dyspepsia subgroups: A population-based study
28. Dyspepsia in consulters and non-consulters: Prevalence, health-care seeking behaviour and risk factors
29. Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in The Netherlands and Japan
30. Occupational factors in the aetiology of gastric and duodenal ulcers with an estimate of their incidence in the general population
31. Studies of the epidemiology of peptic ulcer in a rural community: Prevalence and natural history of dyspepsia and peptic ulcer
32. Functional bowel disorders in apparently healthy people
33. A study of caffeine consumption and symptoms: Indigestion, palpitations, tremor, headache, and insomnia
34. Introduction to the epidemiology of dyspepsia
35. Dyspepsia in England and Scotland
36. Dyspepsia in coalminers and the general population: A comparative study
37. Towards a true prevalence of peptic ulcer: The Sorreisa gastrointestinal disorder study
38. U.S. Householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact
39. Gastroduodenal motility
40. Non-ulcer dyspepsia and Helicobacter pylori in type 2 diabetic patients: Association with autonomic neuropathy
41. Gastroparesis and dyspepsia in patients with diabetes mellitus
42. A comparison of upper gastrointestinal endoscopy and radiography
43. Detection of gastric erosions: Comparison of biphasic radiography with fiberoptic endoscopy
44. Peptic ulcer and gastric carcinoma: Diagnosis with biphasic radiography compared with fiberoptic endoscopy
45. Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study
46. Long-term costs after gastroenterology consultation with endoscopy versus radiography in dyspepsia
47. Complications of diagnostic gastrointestinal endoscopy
48. Sedation for upper gastrointestinal endoscopy: Results of a nationwide survey
49. Cost-effectiveness of screening for colorectal cancer in the general population
50. The detection of colorectal cancer at an asymptomatic stage by screening is useful
51. Cost-effectiveness model for colon cancer screening
52. Cost-Effectiveness of Colonoscopy in Screening for Colorectal Cancer
53. Imaging studies in dyspepsia
54. Discriminant analysis of factors distinguishing patients with functional dyspepsia from patients with duodenal ulcer. Significance of somatization
55. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly
56. Screening for drug related dyspepsia: An analysis of prescription symmetry
57. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs
58. A database on dyspepsia
59. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55?
60. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report
61. Importance of reflux symptoms in functional dyspepsia
62. Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: A medical decision analysis
63. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: Clinical and economic consequences
64. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects
65. Evaluation of initial noninvasive therapy in pediatric patients presenting with suspected ulcer disease
66. The Helicobacter pylori breath test: A surrogate marker for peptic ulcer disease in dyspeptic patients
67. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: A randomised trial
68. Functional dyspepsia. Current treatment recommendations
69. Classification of dyspepsia. Identification of independent symptom components in 7270 consecutive, unselected dyspepsia patients from general practice
70. Prospective screening of dyspeptic patients by Helicobacter pylori serology
71. A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice
72. Accuracy of serology for the diagnosis of Helicobacter pylori infection - A comparison of eight kits
73. Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting
74. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay
75. Diagnostic tests for Helicobacter pylori: A prospective evaluation of their accuracy, without selecting a single test as the gold standard
76. What is behind dyspepsia?
77. Diagnose und therapie der helicobacter pylori infektion. Leitlinien der Deutschen Gesellschaft für Verdauungs, und Stoffwechselkrankhei ten DGVS
78. Cisapride or cimetidine in the treatment of functional dyspepsia. Results of a double-blind, randomized, Swiss multicentre study
79. Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia
80. Smoking, alcohol, and nonsteroidal anti-inflammatory drugs in outpatients with functional dyspepsia and among dyspepsia subgroups
81. Food and nutrient intakes and eating patterns in functional and organic dyspepsia
82. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice
83. Short course acid suppressive treatment for patients with functional dyspepsia: Results depend on Helicobacter pylori status
84. Efficacy of omeprazole in functional dyspepsia: Double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)
85. Pharmacological interventions for non-ulcer dyspepsia
86. Treatment of functional dyspepsia
87. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia
88. Drug treatment of functional dyspepsia: A systematic analysis of trial methodology with recommendations for design of future trials
89. An evidence-based appraisal of reflux disease management - The Genval Workshop Report
90. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia
91. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia
92. Helicobacter pylori infection in children: A consensus statement
93. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients
94. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia
95. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia
96. A double blind randomized, placebo-controlled trial on the effects of a herbal preparation in patients with functional dyspepsia
97. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia
98. Levosulpiride in functional dyspepsia: A multicentric, double-blind, controlled trial
99. L-sulpiride versus metoclopramide in functional dyspepsia: A randomized double-blind study
100. Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia
101. Are psychosocial factors of aetiological importance in functional dyspepsia?
102. Psychological factors and somatic symptoms in functional dyspepsia. A comparison with duodenal ulcer and healthy controls
103. Is there a typical conflict in dyspepsia? An epidemiologic psychoanalytic contribution to the topic of a specific conflict in psychosomatic medicine
104. Psychological factors in functional gastrointestinal disorders: Characteristics of the disorder or of the illness behavior?
105. Dyspepsia in relation to Helicobacter pylori infection and psychosocial work stress in white collar employees
106. Functional gastrointestinal disorders: Psychological, social, and somatic features
107. Psychotherapy in functional dyspepsia
108. Treating nonulcer dyspepsia considering both functional disorders of the digestive system and psychiatric conditions
109. Bundesärztekammer, kassenärztliche bundesvereinigung. Beurteilungskriterien für leitlinien in der medizinischen versorgung
110. International economic impact of functional gastrointestinal disorders
111. Initial management strategies for dyspepsia (Cochrane Review)
112. The effectiveness of endoscopy in the management of dyspepsia: A qualitative systematic review
113. Alternative management strategies for patients with suspected peptic ulcer disease
114. Testen und Behandeln ("Test and Treat"): Eine gültige empfehlung für das management bei dyspepsie
115. Testing for helicobacter Pylori infection: Validation and diagnostic yield of a near patient test in primary care
116. A prospective randomised trial of a test and treat policy versus endoscopy based management in young Helicobacter Pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic
117. Costs and benefits of a test and treat strategy in Helicobacter Pylori infected subjects: A prospective intervention study in general practice
118. Randomised controlled trial of four dyspepsia management strategies in primary care with 12 month follow-up